<DOC>
	<DOCNO>NCT00154115</DOCNO>
	<brief_summary>Prospective , randomize , double blind study investigate efficacy levosimendan heart failure cardiac surgery . Study hypothesis : Levosimendan diminishes need adrenergic inotropic drug morbidity may improve survival heart valve surgery .</brief_summary>
	<brief_title>Levosimendan High Risk Heart Valve Surgery</brief_title>
	<detailed_description>200 patient prospectively randomize double blind study investigate efficacy levosimendan heart failure cardiac surgery . Levosimendan/placebo administer 24 hour continuous infusion begin anesthesia induction . Primary endpoint adrenergic inotrope need cardiopulmonary bypass secondary endpoint hospital 6-month mortality major organ failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Eligible cardiac valve combine CABG cardiac valve surgery : Clinical sign cardiac insufficiency Endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>heart failure</keyword>
	<keyword>levosimendan</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>